Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 1, 2014, Pages

  Wu, Min ^a   Tang, Ri Ning ^a   Liu, Hong ^a   Xu, Min ^a   Pan, Ming Ming ^a   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Chronic kidney disease; Cinacalcet; Endothelial to mesenchymal transition; Parathyroid hormone; Renal fibrosis

Indexed keywords

ADENINE; ALPHA SMOOTH MUSCLE ACTIN; CALCIUM; CALVASCULIN; CD31 ANTIGEN; CINACALCET; COLLAGEN; MESSENGER RNA; PARATHYROID HORMONE; PHOSPHORUS; SC 207438; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

EID: 84891527690     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00375.2013     Document Type: Article

References (42)

1. Belozeroff V, Goodman WG, Ren L, Kalantar-Zadeh K. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol 4: 673-679, 2009.
2. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004.
3. Borchhardt KA, Heinzl H, Mayerwoger E, Horl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 86: 919-924, 2008.
4. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46: 58-67, 2005.
5. Cha H, Jeong HJ, Jang SP, Kim JY, Yang DK, Oh JG, Park WJ. Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med 42: 61-68, 2010.
6. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793-1800, 2005.
7. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA. A randomized, double-blind, placebo-controlled study to access the efficacy and safety of cinacalcet HCl in paticipants with CKD not receiving dialysis. Am J Kidney Dis 53: 197-207, 2009.
8. Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 27: 1437-1445, 2012.
9. Choi SR, Lim JH, Kim MY, Hong YA, Chung BH, Chung S, Choi BS, Yang CW, Kim YS, Chang YS, Park CW. Cinacalcet improves endothelial dysfunction and cardiac hypertrophy inpatients on hemodialysis with secondary hyperparathyroidism. Nephron Clin Pract 122: 1-8, 2012.
10. Choi YJ, Chakraborty S, Nguyen V, Nguyen C, Kim BK, Shim SI, Suki WN, Truong LD. Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of vascular endothelial growth factor. Hum Pathol 31: 1491-1497, 2000.
11. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E. Effect of a magnesiumbase phosphate binder on medial calcification in a rat model of uremia. Kidney Int 83: 1109-1117, 2013.
12. Esposito L, Rostaing L, Gennero I, Mehrenberger M, Durand D, Kamar N. Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. Clin Nephrol 68: 245-248, 2007.
13. Fraser WD. Hyperparathyroidism. Lancet 374: 145-158, 2009.
14. Guo Y, Yuan W, Wang L, Shang M, Peng Y. Parathyroid hormonepotentiated connective tissue growth factor expression in human renal proximal tubular cells through activating the MAPK and NF-κB signaling pathways. Nephrol Dial Transplant 26: 839-847, 2011.
15. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 20: 1370-1377, 2005.
16. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 43: 161-172, 2010.
17. Jung S, Querfeld U, Muller D, Rudolph B, Peters H, Kramer S. Submaximal suppression of parathyroid hormone ameliorates calcitriolinduced aortic calcification and remodeling and myocardial fibrosis in uremic rats. J Hypertens 30: 2182-2191, 2012.
18. Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 170: 1473-1484, 2007.
19. Kwon O, Hong SM, Sutton TA, Temm CJ. Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol 295: F351-F359, 2008.
20. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 175: 1380-1388, 2009.
21. Li J, Qu X, Yao J, Caruana G, Ricardo SD, Yamamoto Y, Yamamoto H, Bertram JF. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 59: 2612-2624, 2010.
22. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005.
23. Loncar G, Bozic B, Dimkovic S, Prodanovic N, Radojicic Z, Cvorovic V, Putnikovic B, Popovic V. Association of increased parathyroid hormone with neuroendocine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest 34: e78-e85, 2011.
24. Ma KL, Liu J, Ni J, Zhang Y, Lv LL, Tang RN, Ni HF, Ruan XZ, Liu BC. Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apoliporotein E knockout mice via endothelial-mesenchymal transition. Int J Med Sci 10: 420-426, 2013.
25. Malluche HH, Monier-Faugere MC, Wang G, Frazã OJM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69: 269-278, 2008.
26. Messa P, Alfieri Brezzi B. Cinacalcet: pharmacological and clinical aspects. Exp Opin Drug Metab Toxicol 4: 1551-1560, 2008.
27. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, Yuzawa Y, Atkinson MA, Johnson RJ, Croker B. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 18: 539-550, 2007.
28. Nicolai A, Li M, Kim DH, Vanella L, Positano V, Gastaldelli A, Rezzani R, Rodella LF, Drummond G, Kusmic C, L'Abbate A, Kappas A, Abraham NG. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension 53: 508-515, 2009.
29. Ochodnicky P, Henning RH, Buikema HJ, de Zeeuw D, Provoost AP, van Dokkum RP. Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat. Am J Physiol Renal Physiol 298: F625-F633, 2010.
30. Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 14: 959-967, 2003.
31. Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M, Covic A, Strippoli GF. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trails. PLoS Med 10: e1001436, 2013.
32. Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294: F748-F757, 2008.
33. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 22: 2831-2837, 2007.
34. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 292: F1215-F1218, 2007.
35. Rutledge MR, Farah V, Adeboye AA, Seawell MR, Bhattacharya SK, Weber KT. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther 27: 161-170, 2013.
36. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 Study Group. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 29: 230-236, 2009.
37. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17: 3383-3393, 2006.
38. Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, Liu B. Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. Cardiovasc Diabetol 9: 31, 2010.
39. Tang RN, Lv LL, Zhang JD, Dai HY, Li Q, Zheng M, Ni J, Ma KL, Liu BC. Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. Int J Cardiol 162: 92-99, 2013.
40. Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 19: 2282-2287, 2008.
41. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13: 952-961, 2007.
42. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, Breyer MD, Harris RC. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 17: 2664-2669, 2006.